

1 **Functional myeloid-derived suppressor cells expand in blood but not airways**
2 **of COVID-19 patients and predict disease severity**

3 Sara Falck-Jones¹, Sindhu Vangeti¹, Meng Yu¹, Ryan Falck-Jones^{2,3}, Alberto Cagigi¹,
4 Isabella Badolati¹, Björn Österberg¹, Maximilian Julius Lautenbach⁴, Eric Åhlberg¹, Ang
5 Lin^{1,5}, Inga Szurgot¹, Klara Lenart¹, Fredrika Hellgren¹, Jörgen Sälde⁶, Jan Albert^{7,8},
6 Niclas Johansson^{4,9}, Max Bell^{2,3}, Karin Loré¹, Anna Färnert^{4,9} and Anna Smed-
7 Sörensen^{1*}

8
9 ¹Division of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet, Karolinska
10 University Hospital, Stockholm, Sweden. ²Department of Physiology and Pharmacology, Karolinska
11 Institutet, Stockholm, Sweden. ³Department of Perioperative Medicine and Intensive Care, Karolinska
12 University Hospital, Stockholm, Sweden. ⁴Division of Infectious Diseases, Department of Medicine
13 Solna, Center for Molecular Medicine, Karolinska Institutet, Sweden. ⁵Stemirna Therapeutics Inc,
14 Shanghai, 201206, China. ⁶Health Care Services Stockholm County (SLSO). ⁷Department of
15 Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden. ⁸Clinical Microbiology,
16 Karolinska University Hospital Solna, Stockholm, Sweden. ⁹Department of Infectious Diseases,
17 Karolinska University Hospital Solna, Stockholm, Sweden.

18
19 * Corresponding author: Dr. Anna Smed-Sörensen, Division of Immunology and
20 Allergy, Department of Medicine Solna, Karolinska Institutet, Visionsgatan 4,
21 BioClinicum J7:30, Karolinska University Hospital, 171 64 Stockholm, Sweden. E-mail:
22 anna.smed.sorensen@ki.se. Phone: +46 (8) 517 768 29.

23 **Running title:** MDSCs expand in severe COVID-19

24 **Keywords:** COVID-19, SARS-CoV-2, monocytic myeloid-derived suppressor cells, T
25 cells, Arginase-1, respiratory immunology.

26 **Word count:** 3480 (excl. Abstract, Methods, Fig. legends, References)

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

27 **Abstract**

28 The immunopathology of COVID-19 remains enigmatic, exhibiting
29 immunodysregulation and T cell lymphopenia. Monocytic myeloid-derived suppressor
30 cells (M-MDSC) are T cell suppressors that expand in inflammatory conditions, but
31 their role in acute respiratory infections remains unclear. We studied blood and airways
32 of COVID-19 patients across disease severity at multiple timepoints. M-MDSC
33 frequencies were elevated in blood but not in nasopharyngeal or endotracheal
34 aspirates of COVID-19 patients compared to controls. M-MDSCs isolated from COVID-
35 19 patients suppressed T cell proliferation and IFN γ production partly via an arginase-
36 1 (Arg-1) dependent mechanism. Furthermore, patients showed increased Arg-1 and
37 IL-6 plasma levels. COVID-19 patients had fewer T cells, and displayed downregulated
38 expression of the CD3 ζ chain. Ordinal regression showed that early M-MDSC
39 frequency predicted subsequent disease severity. In conclusion, M-MDSCs expand in
40 blood of COVID-19 patients, suppress T cells and strongly associate with disease
41 severity, suggesting a role for M-MDSCs in the dysregulated COVID-19 immune
42 response.

43 **Introduction**

44 The pathogenesis of COVID-19 caused by severe acute respiratory syndrome
45 coronavirus-2 (SARS-CoV-2) remains elusive. SARS-CoV-2 infection ranges from
46 asymptomatic disease to multi-organ failure and death¹. COVID-19 is characterized by
47 influenza-like symptoms (including fever, cough and myalgia), and in severe cases,
48 respiratory failure and acute respiratory distress syndrome, occurring in around 40%
49 of hospitalized cases^{1, 2, 3}. Fatal COVID-19 is caused by tissue-directed
50 immunopathology, especially in the lungs, rather than the virus itself^{4, 5}. Furthermore,
51 it is known that immune cells differ depending on their anatomical location^{6, 7, 8, 9, 10}.
52 Therefore, studying both systemic and respiratory immune responses in COVID-19 is
53 important to fully understand its pathogenesis and to identify factors dictating disease
54 severity.

55
56 COVID-19 is associated with substantial immune activation including elevated levels
57 of proinflammatory cytokines such as IL-6¹¹. Furthermore, T cell lymphopenia occurs,
58 especially in critical cases¹², but the underlying mechanism(s) remain unclear. SARS-
59 CoV-2 specific T cells are important in combating the virus¹³, and a functional T cell
60 response is critical for clearing infections in general. Myeloid-derived suppressor cells
61 (MDSCs) are myeloid immune cells with an immature phenotype and potent T cell
62 suppressive capacity^{14, 15, 16}. MDSCs expand in inflammatory conditions including
63 cancer, autoimmune disease and chronic viral infections like HIV and hepatitis C¹⁷.
64 Two subpopulations of MDSCs have been identified based on phenotypic and
65 morphological features: monocytic MDSCs (M-MDSCs) and polymorphonuclear
66 MDSCs (PMN-MDSCs) with partly overlapping functions¹⁸. MDSC driven mechanisms
67 of T cell suppression include secretion of arginase 1 (Arg-1) thereby catabolizing L-

68 arginine, generation of reactive oxygen species (ROS) and nitric oxide (NO), direct
69 engagement of T cell inhibitory and apoptotic receptors, and production of inhibitory
70 cytokines such as IL-10 and TGF- β ¹⁹.

71
72 Single-cell RNA sequencing, mass cytometry and flow cytometry on blood have
73 suggested that expansion of suppressive myeloid cells is a hallmark of severe COVID-
74 19^{20, 21}. Furthermore, high frequency of PMN-MDSCs was recently reported to
75 correlate with disease severity in COVID-19²². However, functional and mechanistic
76 data on the role of M-MDSCs during COVID-19 are lacking, further confounded by the
77 lack of knowledge of the role of M-MDSCs in respiratory infections in general.

78
79 In this study, we investigated M-MDSCs in COVID-19 patients across disease severity
80 and compared to influenza patients and healthy controls. Influenza A virus infection is
81 often compared to COVID-19 due to similarities including the diverse clinical
82 presentation and the route of transmission^{23, 24}. We found a striking association
83 between the frequency of blood M-MDSCs and COVID-19 disease severity. However,
84 the frequency of M-MDSCs from the nasopharynx and lower airways did not correlate
85 with disease severity in COVID-19. Importantly, purified M-MDSCs were functional and
86 suppressed T cell proliferation, partly via an Arg-1 dependent mechanism. In line with
87 this, plasma Arg-1 levels were elevated in COVID-19 patients in a disease severity
88 dependent manner. Finally, we found that early frequency of blood M-MDSCs
89 predicted subsequent disease severity, suggesting both that M-MDSCs are involved
90 in the dysregulation of the immune response in COVID-19 and that they may be used
91 as a potential prognostic marker in COVID-19 patients.

92

93 **Results**

94 ***Study subject characteristics***

95 In total, 147 adults with PCR confirmed SARS-CoV-2 infection, ranging from mild to
96 fatal disease were enrolled in the study: 91 patients from hospital wards, 43 patients
97 from the ICU, 3 patients from an outpatient clinic and 10 household contacts, and blood
98 as well as respiratory samples were collected longitudinally (Figure 1A and
99 Supplementary figure 1). Identical samples from 44 patients with PCR confirmed
100 influenza A virus infection with mild to moderate disease, as well as from 33 age-
101 matched healthy controls (HCs) were included for comparison (Figure 1B and Table
102 1). As expected, disease severity in the COVID-19 patient cohort varied over time
103 (Figure 1C, Table 2 and Supplementary figure 1), and some patients deteriorated
104 during their hospital stay. At peak disease severity, 13% of patients were classified as
105 having mild disease, 39% as moderate, and 39% as severe (Figure 1C). Furthermore,
106 there were 12 recorded fatalities (8.1%) in the COVID-19 cohort during the observation
107 period (Figure 1C). The peak disease severity score prior to death was 6 in all but two
108 patients who had scores of 4 and 5 respectively. At the end of the study period, 110 of
109 the non-fatal, hospitalized patients had been discharged while 12 patients remained in
110 hospital all of whom were already classified as having severe disease. The distribution
111 of age varied significantly across peak disease severity groups in COVID-19 patients
112 ($p < 0.001$), as did body mass index (BMI) ($p < 0.001$), male gender ($p = 0.004$), and CCI
113 ($p = 0.042$) (Table 2).

114

115 ***M-MDSC frequencies are elevated in blood from COVID-19 and influenza***
116 ***patients proportional to disease severity***

117 To investigate the dynamics of M-MDSCs during COVID-19 disease, we performed an
118 extensive analysis of samples from COVID-19 patients across disease severity and
119 compared with samples from influenza patients and HCs. PBMCs and cells from
120 nasopharyngeal aspirates (NPA) and endotracheal aspirates (ETA) were stained and
121 analysed by flow cytometry. M-MDSCs were identified as CD14⁺ cells within the
122 lineage negative (CD3⁻CD56⁻CD19⁻CD20⁻CD66⁻), HLA-DR negative population
123 (Figure 2A). In blood, the peak frequency of M-MDSCs was significantly increased in
124 both COVID-19 patients and influenza patients compared to HCs (Figure 2B). The
125 frequency of M-MDSC in NPA had a higher spread among both HC and patients
126 compared to blood (Figure 2B). Albeit in a small number of patients with mild to
127 moderate disease, influenza patients displayed a clear pattern of elevated frequencies
128 of M-MDSCs in NPA as compared to COVID-19 patients and HCs. The elevated
129 frequency of M-MDSCs in NPA in influenza patients compared to COVID-19 was also
130 evident when comparing only mild and moderate influenza and COVID-19 cases,
131 $p=0.0016$ (data now shown). In contrast to NPA, COVID-19 patients with more severe
132 disease had significantly higher peak M-MDSC frequencies in blood, while COVID-19
133 patients with mild disease had blood M-MDSC frequencies comparable to those seen
134 in HCs (Figure 2C). The frequency of M-MDSC in blood from COVID-19 patients
135 decreased over time (Figure 2D) and returned to similar frequencies as seen in HCs
136 at follow up samples taken during convalescence (33-65 days after study inclusion)
137 (Figure 2E).

138

139 Somewhat surprisingly, COVID-19 patients, in contrast to influenza patients, had low
140 frequencies of M-MDSCs in NPA, even when comparing patients with similar severity
141 of disease (Figure 2B). Since COVID-19 patients on average were included in the
142 study and sampled significantly later after onset of symptoms compared to the
143 influenza patients (18 vs 5 days, respectively), we speculated that the infection-
144 induced inflammation, including infiltration of M-MDSCs, might have transitioned into
145 the lower airways in the COVID-19 patients compared to the influenza patients. To
146 address this, we assessed whether M-MDSCs were present in ETA from the lower
147 airways in 20 intubated COVID-19 patients. However, the frequency of M-MDSCs in
148 ETA was not found to be elevated compared to NPA from the same patients (Figure
149 2F). Although the levels of blood M-MDSCs in COVID-19 patients were significantly
150 elevated compared to HCs, the M-MDSC phenotype with respect to expression levels
151 of CD62L, CCR2 and CD86 were similar (Figure 2G and data not shown). However,
152 respiratory M-MDSCs expressed significantly lower levels of CD62L, CD86 and CCR2
153 compared to blood M-MDSCs (Figure 2G-I). Altogether, these data indicate that severe
154 COVID-19 disease is associated with elevated levels of M-MDSCs in the blood, but
155 not in the respiratory tract, at least at the time points studied.

156

157 ***M-MDSCs isolated from COVID-19 patients suppress CD4 and CD8 T cell*** 158 ***proliferation***

159 To functionally confirm the identity of M-MDSCs in COVID-19 patients, we evaluated
160 their suppressive effect on T cells. COVID-19 patient blood M-MDSCs were purified
161 and co-cultured with CFSE-labelled allogeneic PBMCs, in the presence of SEB for
162 three days (Supplementary figure 3). As expected, SEB induced strong T cell
163 proliferation (Figure 3A). However, addition of M-MDSCs induced a significant

164 suppression of both CD4 and CD8 T cell proliferation in a dose-dependent manner
165 (Figure 3A-C). In line with this, SEB induced high levels of IFN γ secretion that were
166 significantly lower in co-cultures with M-MDSCs present (Figure 3D). Arginase 1 (Arg-
167 1) production is one effector mechanism by which M-MDSCs suppress T cell
168 proliferation via degradation of L-arginine that is needed for proliferation. Indeed,
169 addition of L-arginine to the M-MDSC co-cultures restored the concentration of IFN γ in
170 the cell culture supernatants (Figure 3D). Furthermore, co-cultures with M-MDSCs
171 contained high levels of Arg-1 that was undetectable in cultures without M-MDSCs
172 (Figure 3E). In co-cultures supplemented with L-arginine, Arg-1 was no longer
173 detectable, possibly due to complex formation of Arg-1 and the substrate²⁵ (Figure 3E).
174 Importantly, the addition of recombinant L-arginine to the co-cultures decreased the
175 suppressive effect of M-MDSCs on T cells and partially restored T cell proliferation
176 (Figure 3F-G). This indicates that M-MDSCs from COVID-19 patients use Arg-1 as one
177 mechanism to suppress T cells. In conclusion, blood M-MDSC isolated from COVID-
178 19 patients are functional and can suppress T proliferation and IFN γ secretion in a
179 dose- and Arg-1 dependent manner.

180

181 ***M-MDSC related cytokines are elevated in COVID-19 patients and increase***
182 ***with disease severity***

183 To further investigate the effect of elevated frequencies of blood M-MDSCs in COVID-
184 19 patients, cytokines that have been linked to M-MDSC function and activation were
185 measured in plasma and NPA at the time of study inclusion. In plasma, COVID-19
186 patients had significantly higher levels of Arg-1 than HCs, but no significant difference
187 was observed between COVID-19 patients and influenza patients (Figure 4A).
188 Interestingly, Arg-1 levels in NPA were higher than in plasma in all three groups, with

189 no significant differences between the groups (Figure 4B). Among COVID-19 patients,
190 the plasma concentration of Arg-1 was lower in patients with mild disease compared
191 to patients with moderate, severe and fatal disease ($p=0.07$, $p=0.04$ and $p=0.01$
192 respectively) (Figure 4C).

193
194 Plasma concentrations of IL-6, a potent proinflammatory cytokine important for M-
195 MDSC differentiation¹⁴, were significantly increased in both COVID-19 patients and
196 influenza patients compared to HCs (Figure 4D), while no statistically significant
197 differences were observed in NPA (Figure 4E). Furthermore, levels of IL-6 were
198 strikingly different across the COVID-19 disease severity groups (Figure 4F). Mild
199 COVID-19 patients had significantly lower IL-6 levels than moderate patients
200 ($p=0.038$), severe patients ($p<0.001$) and patients with fatal outcome ($p=<0.01$),
201 respectively. COVID-19 patients with moderate disease also had significantly lower
202 levels than severe patients ($p=0.04$). GM-CSF, which is important for M-MDSC
203 development¹⁴, was also measured in plasma, but was only significantly elevated in
204 influenza patients (Figure 4G). Finally, concentrations of IL-10 and IL-1 β were
205 measured in plasma of a subset of COVID-19 patients with moderate to fatal disease,
206 but only IL-10 showed an association with disease severity (Figure 4H-I). In summary,
207 cytokines involved in the activation and function of M-MDSCs were elevated in plasma
208 from COVID-19 patients, and correlated with disease severity.

209
210 ***T cells are reduced in blood of COVID-19 patients and have low CD3 ζ chain***
211 ***expression***

212 Since M-MDSCs isolated from COVID-19 patients efficiently suppressed T cells *in*
213 *vitro*, the overall blood T cell frequency and function in patients was assessed in the

214 same patients using flow cytometry (Supplementary figure 4). Absolute numbers of
215 peripheral blood CD4+ T cells were decreased in the COVID-19 patients with
216 moderate, severe and fatal disease compared to HCs (p=0.02, p=0.001, p=0.05
217 respectively) (Figure 5A). Similarly, absolute numbers of CD8+ T cells were also
218 significantly decreased in moderate, severe and fatal COVID-19 disease compared to
219 HCs (p=0.004, p=0.005 and p=0.003 respectively) (Figure 5B). However, no
220 correlation between blood M-MDSC frequency and T cell count in COVID-19 patients
221 was found (Figure 5C), either at peak/bottom frequencies or at any of the longitudinal
222 time points studied in each patient (Figure 5C and data not shown).

223
224 Evidence of T cell suppression was further investigated in COVID-19 patients with
225 varying disease severity, influenza patients and HCs by quantifying the surface
226 expression of the CD3 ζ chain, a homodimer chain in the TCR complex involved in T
227 cell proliferation and in secretion of cytokines (Figure 5D). The CD3 ζ chain is
228 downregulated *in vitro* in the absence of L-arginine resulting in decreased T cell
229 proliferation²⁶. We observed that the surface expression of the CD3 ζ chain on CD4+
230 and CD8+ T cells was significantly lower in both COVID-19 and influenza patients
231 compared to HC (Figure 5E-F) suggesting that the T cells may have an impaired
232 functional capacity. In summary, COVID-19 patients had lower T cell frequency and
233 indication of impaired function of the T cells compared to HCs.

234

235 ***Early M-MDSC frequencies predict peak disease severity***

236 To evaluate the effect of blood M-MDSC frequency early during COVID-19 disease on
237 subsequent disease severity, a proportional odds logistic regression was performed
238 (Figure 6A). This yielded a crude odds ratio (OR) of 1.50 (95% CI 1.03 – 2.32),

239 indicating that the M-MDSC frequency in the first two weeks from onset of symptoms
240 could potentially be a predictor of more severe outcome of COVID-19 (Figure 6B).

241
242 As shown above, M-MDSC frequency was higher in COVID-19 patients with more
243 severe disease (Figure 2C), and these patients were both predominantly male and had
244 a significantly higher age compared to COVID-19 patients with less severe disease
245 (Table 1). Therefore, the association between M-MDSC frequency and sex and age
246 was assessed, demonstrating significantly higher levels of M-MDSCs in men (Figure
247 6C) and a significant correlation between age and M-MDSC frequency ($R=0.22$,
248 $p=0.01$) (Figure 6D).

249
250 In summary, early M-MDSC frequencies are associated with subsequent disease
251 severity and appear to be strongly associated with age and sex.

252

253 **Discussion**

254 Understanding the immunopathogenesis of COVID-19 is critical to optimally treat
255 patients and prevent fatal outcome but also to aid in the development of specific
256 therapy and vaccines. One potential player in the immune activation to SARS-CoV-2
257 infection may be MDSCs, a subset of immune cells that in recent years have been
258 intensively studied, by us and others, mainly in relation to cancer and vaccination^{14, 15,}
259 ^{16, 18, 27}. Still, only limited knowledge on how M-MDSCs influence disease severity
260 during infection, including COVID-19, is available. In the present study, the distribution
261 and function of M-MDSCs during COVID-19 were investigated over time and across
262 disease severity in a comparatively large and clinically well-characterized cohort.

263
264 A major finding in the current study is the association between M-MDSC frequency
265 and disease severity in COVID-19 patients. Downregulation of HLA-DR on monocytes
266 has previously been shown in severe COVID-19, possibly reflecting an increase in M-
267 MDSC frequency, and is linked to high levels of IL-6 and lymphopenia²⁸. We observed
268 an increased frequency of blood M-MDSC, both during COVID-19 and influenza,
269 similar to what was previously observed in HIV-1^{17, 29}. While the COVID-19 and the
270 influenza patient cohorts are not completely comparable in disease severity and time
271 of sampling after symptom onset, it is still relevant to know that expansion of M-MDSCs
272 is also observed in another acute respiratory infection, and that this finding is not
273 unique for COVID-19. Furthermore, MDSCs are expanded during sepsis, and are
274 associated with poor outcome³⁰.

275
276 Notably, in influenza patients M-MDSC frequencies were increased in the nasopharynx
277 compared to blood, indicating that M-MDSCs are recruited to the site of infection during

278 influenza similar to what has been observed for other myeloid cells³¹. In contrast, the
279 frequency of M-MDSC in the nasopharynx of COVID-19 patients was similar to HCs.
280 Although SARS-CoV-2 replication is initiated in the upper airways, it frequently
281 progresses to the lower respiratory tract^{32, 33}, and may result in immune cell recruitment
282 in the lower airways. However, we were unable to find higher frequencies of M-MDSCs
283 in ETA than in NPA. Nevertheless, ETA does not necessarily reflect cells in the alveoli,
284 but is rather a reflection of the trachea and bronchi. It is therefore possible that M-
285 MDSCs are present even deeper down in the lungs and/or that the time points we
286 sampled the COVID-19 patients were past the peak accumulation of M-MDSCs in the
287 airways. Alternatively, M-MDSCs could differentiate to more macrophage-like cells at
288 the site of inflammation, as seen after migration to tumor sites^{34, 35}, and not be identified
289 with the flow cytometry staining panel used. Migration of M-MDSC from blood to the
290 site of infection is supported by the fact that M-MDSCs in blood had upregulated
291 CD62L compared to respiratory M-MDSCs. CD62L, or L-selectin is involved in the
292 extravasation of immune cells³⁶. Continued studies are ongoing to further address the
293 kinetics and mechanism of myeloid cell migration in humans.

294
295 Characterizing MDSCs is challenging due to the lack of unique cell surface markers
296 and therefore functional analysis of the cells is critical to validate phenotypic
297 identification^{15, 19}. We verified the suppressive capacity of the M-MDSCs in COVID-19
298 patients and found that HLA-DR- CD14+ cells isolated from COVID-19 patients had a
299 potent suppressive effect on T cells, demonstrating that the M-MDSCs identified by
300 flow cytometry corresponded to suppressive and functionally active cells. Since Arg-1
301 was important for M-MDSC activity *in vitro*, levels were measured in plasma and NPA
302 from patients. As expected, COVID-19 patients had increased level of Arg-1 compared

303 to HCs in plasma. There was also a connection between disease severity and Arg-1
304 level in plasma, although there was no difference between patients with moderate
305 disease to fatal outcome. Interestingly, Arg-1 levels were in general substantially
306 higher in NPA than in plasma for all cohorts, without any association with M-MDSC
307 frequency in NPA. It is known that Arg-1 is constitutively produced in the airways in
308 bronchial epithelial cells, endothelial cells, myofibroblasts and alveolar macrophages.
309 The function, however, is unknown. Arg-1 has been suggested to be involved in
310 regulation of NO and airway responsiveness and tissue repair²⁵. The association
311 between M-MDSC and Arg-1 in the airways merits further examination.

312
313 Several factors are involved in the expansion of M-MDSCs, including IL-6 and GM-
314 CSF¹⁴. In line with previous studies^{12, 28}, we demonstrated a relationship between IL-6
315 and COVID-19 disease severity. The high levels of IL-6 could contribute to the
316 generation of M-MDSCs, especially in patients with severe disease. In contrast to
317 previous reports³⁷, plasma GM-CSF was not elevated in our COVID-19 cohort. Instead,
318 higher levels of GM-CSF were seen in the influenza patient cohort. This could be
319 explained by kinetics: the COVID-19 group had longer duration of symptoms compared
320 to the influenza patients and it is possible that the level of GM-CSF had already
321 decreased. IL-10 is also relevant in respect to MDSCs, since it can be produced by
322 MDSCs^{14, 18}, and plasma levels increased with rising disease severity.

323
324 A decrease in absolute numbers of both CD4+ and CD8+ T cells, in line with the data
325 presented here, has previously been demonstrated in COVID-19 patients with severe
326 disease, but the underlying mechanisms for the decrease are still unknown³⁸. One
327 potential such mechanism could be the downregulation of CD3 ζ chain, that results in

328 impaired T cell proliferation. CD3 ζ chain downregulation on T cells has previously been
329 observed in relation to MDSCs in several conditions including sepsis, hepatitis C
330 infection and gastric cancer^{39, 40, 41}. By establishing an immunosuppressive
331 environment, M-MDSCs might prevent efficient immune activation and impede the
332 development of specific adaptive responses required to clear the infection. We
333 therefore speculate that expansion of M-MDSCs contributes to the immune imbalance
334 described in COVID-19, possibly favouring disease progression.

335
336 There is an urgent need for a better understanding of the pathophysiology of COVID-
337 19, including predictors of disease severity. In the current study, we investigated
338 whether M-MDSC frequencies in blood early in disease (before patients develop
339 severe disease) could affect disease outcome. Although our analysis should be
340 interpreted with caution because of low power and possible risk of overfitting when
341 adjusting for age and sex, it clearly suggests elevated M-MDSC frequency in the first
342 two weeks from onset of symptoms as a risk factor for poorer disease outcome. Our
343 protein and functional M-MDSC COVID-19 data is in line with emerging RNA seq data
344 that identify a population likely to be M-MDSCs that is associated with severe COVID-
345 19²¹. Previous research has shown age and male gender are risk factors for severe
346 COVID-19⁴². Furthermore, it is known that MDSCs increase with age as part of the
347 “inflammaging” process (the inflammation seen in ageing)⁴³, but little is known about
348 gender differences. In line with this, we found a correlation between M-MDSC
349 frequency and both age and male gender in this cohort, possibly partly explaining the
350 increased morbidity seen in men and older patients.

351

352 In summary, we have shown that M-MDSCs are expanded in both COVID-19 and
353 influenza and are associated with disease severity in COVID-19 patients, especially in
354 men and older individuals. Although we found indirect indications of M-MDSC
355 migration, we were unable to show an increased M-MDSC frequency in respiratory
356 mucosa in the same way as in influenza, presenting an area of future research. In this
357 study we also demonstrated that M-MDSCs isolated from COVID-19 patients are
358 effective T cell suppressors *in vitro* and may partly explain the detrimental decrease of
359 T cells in patients with severe COVID-19. Finally, we showed that M-MDSCs may
360 predict disease outcome. The findings of this study provide yet another important piece
361 to the puzzle of fully comprehending the immunologic profile of COVID-19 and can
362 potentially contribute to future therapeutic and diagnostic advancements.

363 **Methods**

364 ***Ethics statement***

365 The study was approved by the Swedish Ethical Review Authority, and performed
366 according to the Declaration of Helsinki. Written informed consent was obtained from
367 all patients and controls. For sedated patients, the denoted primary contact was
368 contacted and asked about the presumed will of the patient and, if applicable, to give
369 initial oral and subsequently signed written consent. When applicable retrospective
370 written consent was obtained from patients with non-fatal outcomes.

371

372 ***Study subjects***

373 Inclusion of COVID-19 patients was performed at Karolinska University Hospital and
374 Haga Outpatient Clinic (Haga Näraikut), Stockholm, Sweden during March-May 2020.
375 Inclusion was performed at various levels of care, ranging from primary to intensive
376 care. Inclusion criteria were age >18 years and PCR-confirmed SARS-CoV-2 infection.
377 In order to recruit mild/asymptomatic cases, household contacts of COVID-19 patients
378 were screened with PCR and recruited if positive. Similarly, adult patients with PCR-
379 confirmed influenza A virus infection were recruited during January-March 2019 and
380 2020. A cohort of healthy controls (HCs) (i.e. confirmed influenza A virus and SARS-
381 CoV-2 negative by PCR) was recruited and sampled in the same way as study patients.

382

383 Degree of respiratory failure was categorized daily according to the respiratory domain
384 of the Sequential Organ Failure Assessment score (SOFA)⁴⁴. If arterial partial pressure
385 of oxygen (PaO₂) was not available, peripheral transcutaneous hemoglobin saturation
386 (SpO₂) was used instead and the modified SOFA score (mSOFA) was calculated⁴⁵.
387 Fraction of inspired oxygen (FiO₂) estimation based on O₂ flow was done in

388 accordance with the Swedish Intensive Care register definition as defined at
389 (<https://icuregswe.org/globalassets/riktlinjer/sofa.pdf>, accessed on 7 Sep. 20). Patients
390 were subsequently categorized based on the peak respiratory SOFA or mSOFA value.
391 The 5-point respiratory SOFA score was then extended with an additional level to
392 distinguish admitted mild cases from non-admitted mild cases. Finally, fatal outcome
393 was added as a seventh level, with peak disease severity score 6 prior to death in all
394 but two patients who had scores of 4 and 5, respectively. Additionally, the resulting 7-
395 point composite peak severity score was condensed into a classification consisting of
396 mild (1-2), moderate (3-4), severe (5-6), and fatal (7) disease (Supplementary Tables
397 1 and 2).

398
399 Medical records were reviewed for clinical history, laboratory analyses, medications,
400 previous diseases and co-morbidities, and risk factors. Total burden of comorbidities
401 was assessed using the Charlson co-morbidity index (CCI)⁴⁶.

402
403 ***Collection of respiratory and blood samples***

404 Nasopharyngeal aspirates (NPA) were collected from COVID-19 and influenza
405 patients and HCs where possible, and endotracheal aspirates (ETA) were collected
406 from intubated COVID-19 patients in the ICU. Venous blood was collected in EDTA-
407 containing tubes from all non-ICU patients and controls. In ICU patients, blood was
408 pooled from heparin-coated blood gas syringes discarded in the last 24 hours. In some
409 ICU patients, additional venous blood samples were also collected in EDTA tubes.
410 Routine clinical chemistry analysis was performed on all study subjects including HCs.
411 Admitted patients were sampled at up to four timepoints and discarded ICU patient
412 material was collected up to ten timepoints.

413

414 ***Isolation of cells from blood and nasopharyngeal aspirates***

415 NPA samples were centrifuged at 400g/5 min/ room temperature (RT). Supernatant
416 was collected and frozen at -20°C. Cells were washed with sterile PBS and mucus was
417 removed using a 70 µm cell strainer. Blood samples were centrifuged at 800g/8 min/
418 RT. Plasma was collected and frozen at -20°C. The cellular fraction was diluted with
419 sterile PBS and PBMCs isolated by density-gradient centrifugation at 900g/25 min/RT
420 (without brake), using Ficoll-Paque Plus (GE Healthcare). Cell count and viability were
421 assessed using Trypan Blue (Sigma) exclusion with an automated Countess cell
422 counter (Invitrogen). Cells were stained fresh for flow cytometry analysis. Excess
423 PBMCs were cryopreserved in FBS (Gibco) with 10% DMSO (Sigma) and stored in
424 liquid nitrogen.

425

426 ***Flow cytometry***

427 Cells were stained using Live/Dead Blue (Invitrogen), incubated with human FcR
428 blocking reagent (Miltenyi Biotec) and stained with antibodies against the following
429 surface proteins: CD1c (AD5-8E7; Miltenyi Biotec), CD3 (SK7; BD), CD11c (B-Ly6;
430 BD), CD14 (M5E2; BD), CD16 (3GE; BioLegend), CD19 (HIB19; BioLegend), CD20
431 (L27; BD), CD45 (HI30; BD), CD56 (HCD56; BD), CD62L (SK11; BD), CD66abce
432 (TET2; Miltenyi Biotec), CD86 (2331; BD), CD123 (7G3; BD), CD141 (AD5-14H12;
433 Miltenyi Biotec), CCR2 (K036C2; BioLegend), CCR7 (150503; BD) and HLA-DR
434 (TU36; Life Technologies). If enough cells were available, a second staining was
435 performed using CD3 (SP34-2; BD), CD4 (L200; BD), CD11c (B-ly6; BD), CD14
436 (M5E2; BD), CD16 (3G8; BD), CD19 (SJ25-C1; Thermo Fisher Scientific), CD45 (HI30;
437 BD), CD56 (HCD56; BioLegend), CD66abce (TET2; Miltenyi Biotec), CD123 (7G3;

438 BD), LOX-1 (15C4; BioLegend) and HLA-DR (L243; BioLegend). All stainings were
439 performed at 4°C for 20 minutes. Cells were washed with PBS and fixed with 1-2%
440 paraformaldehyde.

441
442 The expression of CD247 (TCR ζ , CD3 ζ) on CD4 and CD8 T cells was evaluated by
443 intracellular staining. Briefly, following surface staining with Live/Dead Blue
444 (Invitrogen), CD3 (SP34-2; BD), CD4 (L200; BD) and CD8 (SK1; BD), cells were fixed
445 and permeabilized with permeabilization buffer (Thermo Fisher Scientific) and then
446 stained with anti-CD247 (6B10.2; BioLegend) at 4°C for 20 min. Samples were
447 acquired on LSRFortessa flow cytometer (BD Biosciences). Data were analysed using
448 FlowJo software 10.5.3 (TreeStar). Absolute numbers of CD4 and CD8 T cells were
449 calculated by multiplying the frequency of T cells out of total lymphocytes obtained
450 from flow cytometry data with the lymphocyte count from differential cell counts. If
451 multiple T cell frequencies were available from the same patient, the lowest T cell count
452 was used. If absolute lymphocyte count was missing, a value was linearly interpolated
453 between existing values if no more than 7 days apart.

454
455 ***M-MDSC T cell suppression assay***

456 M-MDSCs (HLA-DR⁻ CD14⁺ cells) were purified from frozen PBMCs of three COVID-
457 19 patients, following a protocol developed by Lin et al¹⁶. HLA-DR⁺ cells were depleted
458 using anti-HLA-DR microbeads and an LD column. From the negative fraction,
459 CD14⁺ cells were positively selected using anti-CD14 microbeads. MS columns and
460 MACS separators (all Miltenyi Biotec) were used for the cell sorting. Approximately 0.2
461 million M-MDSCs were obtained from 25-30 million PBMCs, with a viability >90% and
462 purity >85%. In parallel, cryopreserved PBMCs from a buffy coat were thawed and 4

463 million cells were labelled with CFSE (Thermofisher). The previously purified M-
464 MDSCs were co-cultured with 0.5 million of the CFSE-labelled PBMCs, at a ratio of 1:2
465 or 1:5, in the presence of 0.1 µg/mL staphylococcal enterotoxin B (SEB) (Sigma-
466 Aldrich) or 200µg/mL L-arginine (Sigma-Aldrich). The cells were incubated for 3 days
467 at 37°C, in RPMI 1640 (Sigma-Aldrich) medium supplemented with 10% FCS, 5 mM
468 L-glutamine, 100 U/mL penicillin and streptomycin (all Invitrogen). Supernatants were
469 collected from cultures to measure secreted arginase-1 (Invitrogen) and IFN γ (R&D
470 Systems) by ELISA. The cells were washed and surface-stained with CD3 (SK7), CD4
471 (OKT4), and CD8 (SK1) (all from BD Biosciences). Flow cytometry (LSRFortessa, BD
472 Biosciences) was performed as described above and T cell proliferation was
473 measured, by calculating the percentage of CFSE^{low} T cells.

474

475 ***Cytokine analysis***

476 Cytokine levels were measured in plasma samples, NPA supernatants and culture
477 supernatants using enzyme-linked immunosorbent assay (ELISA). IL-6, GM-CSF and
478 IFN γ ELISAs were performed using DuoSet® kits (R&D Systems). Arginase-1 ELISA
479 was performed using Arginase-1 Human ELISA Kit (ThermoFisher). Levels of IL-10
480 and IL-1 β were analyzed at Karolinska University Laboratory using Roche Cobas e602.

481

482 ***Serology***

483 Antibodies against the SARS-Cov-2 Spike (S) trimer were assessed by ELISA.
484 Recombinant proteins were received through the global health-vaccine accelerator
485 platforms (GH-VAP) funded by the Bill and Melinda Gates foundation. Briefly, 96-well
486 plates were coated with 100ng/well of S protein. Plates were incubated with a selected
487 duplicate dilution (1:50) of each plasma sample at ambient temperature for 2 hours.

488 Detection was performed with a goat anti-human IgG HRP-conjugated secondary
489 antibody (clone G18-145 from BD Biosciences) followed by incubation with TMB
490 substrate (BioLegend; cat# 421101) and stopped with a 1M solution of H₂SO₄.
491 Absorbance was read at 450nm+550nm background correction using an ELISA
492 reader. Data are reported as the average optical density (OD) value of the two
493 duplicates.

494

495 ***Statistical analysis***

496 Data analysis was performed in RStudio version 1.2 (RStudio Inc., Boston, MA),
497 GraphPad Prism version 8.0 (GraphPad Software Inc., San Diego, CA) and Microsoft
498 Excel (Microsoft Corp., Redmond, WA). Routine analyses excluding cytokines and
499 flow-cytometry data were assumed to have a standard distribution and means were
500 compared using either an independent Student's t-test or a one-way analysis of
501 variance (ANOVA). Nominal patient characteristics were compared between groups
502 using a Pearson Chi-Squared test or Fisher's exact test depending on if the expected
503 count of any cell was above or below five. Cytokine and flow cytometry data were
504 presumed to have a non-standard distribution and medians were thus compared using
505 the Wilcoxon-Mann-Whitney U or Kruskal-Wallis tests depending on number of
506 cohorts. Post-hoc testing after Kruskal-Wallis was performed using Dunn's test of
507 multiple comparisons or by controlling the False Discovery Rate using Benjamini,
508 Krieger and Yekutieli's an adaptive linear step-up procedure. Non-parametric
509 comparisons of dependent data were performed using Wilcoxon's Signed Ranks test.
510 For correlation analyses of continuous data, Spearman's Rho was used. Finally, a
511 proportional odds logistic regression model was constructed to evaluate predictive

512 capacity of M-MDSC frequencies on disease severity. A 95% significance level was
513 used throughout the study.

514

515 Missing daily severity score data was approximated using a last-observation-carried-
516 forward (LOCF) method. For flow cytometry data, the peak M-MDSC frequency and
517 lowest T cell count were extracted. The peak value for routine laboratory analyses was
518 extracted separately for each analysis except in the case of blood differential counts in
519 which all counts were extracted for the timepoint of lowest lymphocyte count. The
520 ordinal logistic regression model was based on a subset of patients with M-MDSC-
521 frequencies sampled within two weeks of onset of symptoms and before potential ICU
522 admission and who had a disease severity score less than five on the day of sampling.
523 In the event of multiple timepoints for one patient during that period, peak M-MDSC-
524 frequency was used.

525

526 **Acknowledgments**

527 We thank the patients and healthy volunteers who have contributed to this study. We
528 would also like to thank medical students and hospital staff for assistance with patient
529 sampling and collection of clinical data. This work was supported by grants from the
530 Swedish Research Council, the Swedish Heart-Lung Foundation, the Bill and Melinda
531 Gates Foundation, the Knut and Alice Wallenberg Foundation and Karolinska Institutet.
532 We like to thank Drs. Deleah Pettie, Michael Murphy, Lauren Carter and Neil P. King
533 from the Department of Biochemistry, University of Washington, Seattle, WA, USA and
534 Institute for Protein Design, University of Washington, Seattle, WA, USA for the
535 production of viral proteins used in the antibody assay.

536

537 **Contributions**

538 SF-J, SV, AL, KLo, NJ, AF and AS-S planned the study. SF-J, SV, MY, AC, IB, BÖ,
539 MJL, IS, KLe, FH performed experiments. SF-J, RF-J, BÖ, EÅ, JS, MB, NJ, AF
540 included and sampled patients and collected clinical data. JA provided relevant
541 anonymized patient clinical data. SF-J, SV, MY, RF-J, AC, IB and MJL analyzed data.
542 SF-J, MY, RF-J and MJL prepared figures. SF-J and AS-S wrote the manuscript. All
543 co-authors edited the manuscript.

544

545 **Competing interests**

546 The authors declare no competing interests.

547

548 References

- 549 1. Zhou, F. *et al.* Clinical course and risk factors for mortality of adult inpatients
550 with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* **395**,
551 1054-1062 (2020).
552
- 553 2. Huang, C. *et al.* Clinical features of patients infected with 2019 novel
554 coronavirus in Wuhan, China. *Lancet* **395**, 497-506 (2020).
555
- 556 3. Wu, C. *et al.* Risk Factors Associated With Acute Respiratory Distress
557 Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia
558 in Wuhan, China. *JAMA Intern Med* **180**, 1-11 (2020).
559
- 560 4. Ackermann, M. *et al.* Pulmonary Vascular Endothelialitis, Thrombosis, and
561 Angiogenesis in Covid-19. *N Engl J Med* **383**, 120-128 (2020).
562
- 563 5. Vabret, N. *et al.* Immunology of COVID-19: Current State of the Science.
564 *Immunity* **52**, 910-941 (2020).
565
- 566 6. Baharom, F. *et al.* Dendritic Cells and Monocytes with Distinct Inflammatory
567 Responses Reside in Lung Mucosa of Healthy Humans. *J Immunol* **196**, 4498-
568 4509 (2016).
569
- 570 7. Vangeti, S. *et al.* Human Blood and Tonsil Plasmacytoid Dendritic Cells
571 Display Similar Gene Expression Profiles but Exhibit Differential Type I IFN
572 Responses to Influenza A Virus Infection. *J Immunol* **202**, 2069-2081 (2019).
573
- 574 8. Yu, Y.R. *et al.* Flow Cytometric Analysis of Myeloid Cells in Human Blood,
575 Bronchoalveolar Lavage, and Lung Tissues. *Am J Respir Cell Mol Biol* **54**, 13-
576 24 (2016).
577
- 578 9. von Garnier, C. *et al.* Anatomical location determines the distribution and
579 function of dendritic cells and other APCs in the respiratory tract. *J Immunol*
580 **175**, 1609-1618 (2005).
581
- 582 10. Desch, A.N. *et al.* Flow Cytometric Analysis of Mononuclear Phagocytes in
583 Nondiseased Human Lung and Lung-Draining Lymph Nodes. *Am J Respir Crit*
584 *Care Med* **193**, 614-626 (2016).
585
- 586 11. Del Valle, D.M. *et al.* An inflammatory cytokine signature helps predict COVID-
587 19 severity and death. Preprint at:
588 <https://medrxiv.org/content/10.1101/2020.05.28.20115758v1> (2020).
589
- 590 12. Merad, M. & Martin, J.C. Pathological inflammation in patients with COVID-19:
591 a key role for monocytes and macrophages. *Nat Rev Immunol* **20**, 355-362
592 (2020).
593
- 594 13. Sekine, T. *et al.* Robust T cell immunity in convalescent individuals with
595 asymptomatic or mild COVID-19. Preprint at:
596 <https://biorxiv.org/content/10.1101/2020.06.29.174888v1> (2020).

- 597
598 14. Gabrilovich, D.I. & Nagaraj, S. Myeloid-derived suppressor cells as regulators
599 of the immune system. *Nat Rev Immunol* **9**, 162-174 (2009).
600
601 15. Cassetta, L. *et al.* Deciphering myeloid-derived suppressor cells: isolation and
602 markers in humans, mice and non-human primates. *Cancer Immunol*
603 *Immunother* **68**, 687-697 (2019).
604
605 16. Lin, A. *et al.* Rhesus Macaque Myeloid-Derived Suppressor Cells Demonstrate
606 T Cell Inhibitory Functions and Are Transiently Increased after Vaccination. *J*
607 *Immunol* **200**, 286-294 (2018).
608
609 17. Wang, J. *et al.* Effect of TLR agonists on the differentiation and function of
610 human monocytic myeloid-derived suppressor cells. *J Immunol* **194**, 4215-
611 4221 (2015).
612
613 18. Kumar, V., Patel, S., Tcyganov, E. & Gabrilovich, D.I. The Nature of Myeloid-
614 Derived Suppressor Cells in the Tumor Microenvironment. *Trends Immunol*
615 **37**, 208-220 (2016).
616
617 19. Bruger, A.M. *et al.* How to measure the immunosuppressive activity of MDSC:
618 assays, problems and potential solutions. *Cancer Immunol Immunother* **68**,
619 631-644 (2019).
620
621 20. Schulte-Schrepping, J. *et al.* Suppressive myeloid cells are a hallmark of
622 severe COVID-19. Preprint at:
623 <https://medrxiv.org/content/10.1101/2020.06.03.20119818v1> (2020).
624
625 21. Kvedaraite, E. *et al.* Perturbations in the mononuclear phagocyte landscape
626 associated with COVID-19 disease severity. Preprint at:
627 <https://medrxiv.org/content/10.1101/2020.08.25.20181404v1> (2020).
628
629 22. Agrati, C. *et al.* Expansion of myeloid-derived suppressor cells in patients with
630 severe coronavirus disease (COVID-19). *Cell Death Differ*, 1-12 (2020).
631
632 23. Tang, X. *et al.* Comparison of Hospitalized Patients With ARDS Caused by
633 COVID-19 and H1N1. *Chest* **158**, 195-205 (2020).
634
635 24. Petersen, E. *et al.* Comparing SARS-CoV-2 with SARS-CoV and influenza
636 pandemics. *Lancet Infect Dis* **20**, 238-244 (2020).
637
638 25. Maarsingh, H., Pera, T. & Meurs, H. Arginase and pulmonary diseases.
639 *Naunyn Schmiedebergs Arch Pharmacol* **378**, 171-184 (2008).
640
641 26. Taheri, F. *et al.* L-Arginine regulates the expression of the T-cell receptor zeta
642 chain (CD3zeta) in Jurkat cells. *Clin Cancer Res* **7**, 958s-965s (2001).
643
644 27. Bronte, V. *et al.* Recommendations for myeloid-derived suppressor cell
645 nomenclature and characterization standards. *Nat Commun* **7**, 12150 (2016).
646

- 647 28. Giamarellos-Bourboulis, E.J. *et al.* Complex Immune Dysregulation in COVID-
648 19 Patients with Severe Respiratory Failure. *Cell Host Microbe* **27**, 992-
649 1000.e1003 (2020).
650
- 651 29. Medina, E. & Hartl, D. Myeloid-Derived Suppressor Cells in Infection: A
652 General Overview. *J Innate Immun* **10**, 407-413 (2018).
653
- 654 30. Schrijver, I.T., Théroude, C. & Roger, T. Myeloid-Derived Suppressor Cells in
655 Sepsis. *Front Immunol* **10**, 327 (2019).
656
- 657 31. Oshansky, C.M. *et al.* Mucosal immune responses predict clinical outcomes
658 during influenza infection independently of age and viral load. *Am J Respir Crit*
659 *Care Med* **189**, 449-462 (2014).
660
- 661 32. Hoffmann, M. *et al.* SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2
662 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell* **181**, 271-
663 280.e278 (2020).
664
- 665 33. Hou, Y.J. *et al.* SARS-CoV-2 Reverse Genetics Reveals a Variable Infection
666 Gradient in the Respiratory Tract. *Cell* **182**, 429-446 (2020).
667
- 668 34. Corzo, C.A. *et al.* HIF-1 α regulates function and differentiation of myeloid-
669 derived suppressor cells in the tumor microenvironment. *J Exp Med* **207**,
670 2439-2453 (2010).
671
- 672 35. Tcyganov, E., Mastio, J., Chen, E. & Gabrilovich, D.I. Plasticity of myeloid-
673 derived suppressor cells in cancer. *Curr Opin Immunol* **51**, 76-82 (2018).
674
- 675 36. Springer, T.A. Traffic signals for lymphocyte recirculation and leukocyte
676 emigration: the multistep paradigm. *Cell* **76**, 301-314 (1994).
677
- 678 37. Wang, J., Jiang, M., Chen, X. & Montaner, L.J. Cytokine storm and leukocyte
679 changes in mild versus severe SARS-CoV-2 infection: Review of 3939
680 COVID-19 patients in China and emerging pathogenesis and therapy
681 concepts. *J Leukoc Biol* **108**, 17-41 (2020).
682
- 683 38. He, R. *et al.* The clinical course and its correlated immune status in COVID-19
684 pneumonia. *J Clin Vir* **127**, 104361 (2020).
685
- 686 39. Darcy, C.J. *et al.* Neutrophils with myeloid derived suppressor function deplete
687 arginine and constrain T cell function in septic shock patients. *Crit Care* **18**,
688 R163 (2014).
689
- 690 40. Zeng, Q.L. *et al.* Myeloid-derived suppressor cells are associated with viral
691 persistence and downregulation of TCR ζ chain expression on CD8(+) T cells
692 in chronic hepatitis C patients. *Mol Cells* **37**, 66-73 (2014).
693
- 694 41. Wang, L. *et al.* Increased myeloid-derived suppressor cells in gastric cancer
695 correlate with cancer stage and plasma S100A8/A9 proinflammatory proteins.
696 *J Immunol* **190**, 794-804 (2013).

- 697
698 42. Zheng, Z. *et al.* Risk factors of critical & mortal COVID-19 cases: A systematic
699 literature review and meta-analysis. *J Infect* **81**, 16-25 (2020).
700
701 43. Salminen, A., Kaarniranta, K. & Kauppinen, A. The role of myeloid-derived
702 suppressor cells (MDSC) in the inflammaging process. *Ageing Res Rev* **48**, 1-
703 10 (2018).
704
705 44. Vincent, J.L. *et al.* The SOFA (Sepsis-related Organ Failure Assessment)
706 score to describe organ dysfunction/failure. On behalf of the Working Group
707 on Sepsis-Related Problems of the European Society of Intensive Care
708 Medicine. *Intensive Care Med* **22**, 707-710 (1996).
709
710 45. Grissom, C.K. *et al.* A modified sequential organ failure assessment score for
711 critical care triage. *Disaster Med Public Health Prep* **4**, 277-284 (2010).
712
713 46. Charlson, M.E., Pompei, P., Ales, K.L. & MacKenzie, C.R. A new method of
714 classifying prognostic comorbidity in longitudinal studies: development and
715 validation. *J Chronic Dis* **40**, 373-383 (1987).
716
717




Figure 1. Study outline. (A) Blood and nasopharyngeal aspirates (NPA) were collected from COVID-19 patients, influenza patients and healthy controls. From ICU patients, endotracheal aspirates (ETA) were also collected. Cells were isolated from blood (PBMCs), NPA and ETA and were analyzed fresh using flow cytometry, and used for functional experiments. Aspirates and plasma were collected and used for serology and cytokine detection using ELISA. (B) Study subjects were included and sampled across disease severity, ranging from healthy controls (n=33) to mild or moderate influenza disease (n=44) and mild to fatal COVID-19 (n=147). (C) Pie charts show distribution of disease severity at time of inclusion and the peak disease severity of COVID-19 patients. At time of inclusion: mild 18%, moderate 52% and severe 31%. At peak disease severity: mild 12%, moderate 39%, severe 41% and fatal outcome 8%.












Figure 2. Frequency of respiratory and blood M-MDSC in COVID-19 patients, influenza patients and HCs. (A) Gating strategy to identify monocytic myeloid-derived suppressor cells (M-MDSCs) by flow cytometry. Live, single CD45⁺ leukocytes were identified and cells expressing CD3, CD19, CD20, CD56, and CD66abce (lineage) and HLA-DR excluded. Among lineage-, HLA-DR- cells, CD14⁺ M-MDSCs were identified. **(B)** Frequency of M-MDSCs per live CD45⁺ cells in blood and NPA. HCs (blue): n=12 (blood), 7 (NPA). Influenza patients (open circles): n=19 (blood), 9 (NPA). COVID-19 patients (closed circles): n=140 (blood), 28 (NPA). Points color-coded by peak severity. **(C)** Peak frequency of blood M-MDSCs per live CD45⁺ cells across disease severity. HCs (blue): n=12. COVID-19 patients (color-coded by peak severity): mild (n=19), moderate (n=53), severe (n=56) and fatal (n=12). **(D)** Blood M-MDSC frequency grouped by peak severity over time in COVID-19 patients. Line shows locally estimated scatterplot smoothing (LOESS) with shaded 95% CI (fatal group CI very wide, not presented). **(E)** Frequency of blood M-MDSCs in paired acute and convalescent samples from COVID-19 patients (n=6). **(F)** M-MDSC frequency in blood, NPA and ETA samples from severe (red) and fatal (grey) COVID-19 patients. **(G-I)** Surface expression on M-MDSCs in HCs (blue) and COVID-19 patients (black) from blood, NPA and ETA of **(G)** CD62L **(H)** CD86 **(I)** CCR2. **(B, C, F-I)** Comparisons of M-MDSC frequencies were performed using the non-parametric Kruskal-Wallis test and subsequent Dunn's post-hoc test of multiple comparisons. In strip charts, group medians are presented as horizontal lines and individual patients as jitter points.




Figure 3. M-MDSCs isolated from COVID-19-patients suppress T cell proliferation partly through release of Arginase-1. (A) Blood M-MDSC isolated from COVID-19 patients were co-cultured with CFSE-labeled allogenic PBMCs in the presence of SEB for 3 days, at a ratio of 1:2 (M-MDSC:PBMC). Histograms show representative CD4 and CD8 T cell proliferation as assessed by CFSE dilution and flow cytometry. Number indicate frequency of proliferating T cells. (B) Bar graphs showing percentage of proliferating CD4 and CD8 cells with mean \pm SEM (n=3). Statistical testing performed using Wilcoxon signed ranks test. (C) Isolated M-MDSC were cultured with CFSE-labelled allogenic PBMCs in the presence of SEB for 3 days. The ratio of M-MDSC: PBMC were 1:5 and 1:2. Bar graphs show percentage of proliferating CD4 T and CD8 cells with mean \pm SEM (n=2). (D) Bar graphs show levels of IFN γ in supernatants from cell cultures with mean \pm SEM (n=2). (E to G) Isolated M-MDSC were cultured with CFSE-labelled allogenic PBMCs in the presence of SEB and L-arginine for 3 days. The ratio of M-MDSC: PBMC was 1:2. (E) Bar graphs show levels of Arginase-1 in supernatants from cell cultures with mean \pm SEM (n=2). (F and G) Bar graphs show percentage of proliferating (F) CD4 T cells and (G) CD8 T cells (n=2) with mean \pm SEM (n=2).

● HC ● COVID-19 ● Mild COVID-19 ● Moderate COVID-19 ● Severe COVID-19 ● Fatal COVID-19 ● Influenza ● Mild influenza ● Moderate influenza




Figure 4. Levels of cytokines in blood and NPA from HCs, COVID-19 patients and influenza patients. (A-C) Arginase-1 was measured in **(A)** plasma, **(B)** NPA and **(C)** across COVID-19 disease severity in plasma. HCs (blue points): n=5 (blood), 5 (NPA). Influenza patients (open circles): n=6 (blood), 3 (NPA). COVID-19 patients (closed circles): n=93 (blood), 13 (NPA). COVID-19 patients (color-coded by peak severity): mild (n=8), moderate (n=41), severe (n=36) and fatal (n=8). **(D-F)** display IL-6 as measured in **(D)** plasma, **(E)** NPA and **(F)** IL-6 across COVID-19 disease severity in plasma. HCs (blue points): n=11 (blood), 3 (NPA). Influenza patients (open circles): n=37 (blood), 24 (NPA). COVID-19 patients (closed circles): n=133 (blood), 7 (NPA). COVID-19 patients (color-coded by peak severity): mild (n=14), moderate (n=56), severe (n=52) and fatal (n=11). **(G)** GM-CSF in plasma comparing HCs and patients. **(H)** IL-10 and **(I)** IL-1B in plasma from patients with moderate to severe disease or fatal outcome. HCs (blue points): n=9. Influenza patients (open circles): n=13. COVID-19 patients (closed circles): n=106. COVID-19 patients (color-coded by peak severity): mild (n=12), moderate (n=38), severe (n=48) and fatal (n=8). **(A-I)** Medians were compared using the non-parametric Kruskal-Wallis test. Post-hoc testing was carried out while controlling the False Discovery Rate **(A-C)** or by using Dunn's test of multiple comparisons **(D-I)**. In strip charts, group medians are presented as horizontal lines and individual patients as jitter points.








Figure 5. T cells in COVID-19 patients. (A-B) Total lowest CD4 and CD8 T cell count in blood was calculated in HCs (n=9) and COVID-19 patients across disease severity, mild (n=8), moderate (n=29), severe (n=32), fatal (n=7). **(C)** Spearman correlation between total CD3⁺ T cell count in blood and peak M-MDSC frequency. **(D)** Gating strategy for CD3 ζ chain analysis. Live, single CD3⁺ cells were identified, and separated into CD4⁺ or CD8⁺ T cells. MFI was calculated for both populations. The blue histogram represents the fluorescence-minus-one control (FMO) and the red histogram represents CD3 ζ (PE-labelled). **(E-F)** Thawed PBMCs from 11 COVID-19 patients, 4 influenza patients and 12 matched healthy controls were intracellularly stained for CD3 ζ chain expression. Median fluorescent intensity (MFI) was calculated for **(E)** CD4⁺ and **(F)** CD8⁺ T cells. Comparison of medians between groups was performed using Kruskal-Wallis' test and subsequent post-hoc testing by Dunn's test of multiple comparisons.

A




B



● HC ● COVID-19 ● Mild COVID-19 ● Moderate COVID-19 ● Severe COVID-19 ● Fatal COVID-19

C



D




Figure 6. M-MDSC frequency predicts disease severity and is associated with male gender and age. (A) Criteria for inclusion in the ordinal logistic regression model. Only patients with up to 2 weeks of symptoms and disease severity <5 that had not yet been admitted to the ICU were included in the analysis **(B)** Proportional odds logistic regression showing predictive capacity of M-MDSC-frequency on peak disease severity score. Crude and adjusted odds ratio presented. **(C)** Peak M-MDSC frequency in men and women compared using Wilcoxon-Mann-Whitney-U **(D)** Spearman correlation between age and peak M-MDSC frequency.

Table 1. Patient and control characteristics

Cohort	COVID-19	Influenza	HC	Sig.¹
n	147	44	33	
Age, mean (range)	57 (24-78)	52 (18-88)	51 (24-80)	*
Male gender, n (%)	109 (74%)	19 (43%)	23 (70%)	
Onset to admission, days, mean (SD)	10 (5.8)	5 (3.2)	-	*
Onset to inclusion, days, mean	18 (10)	5 (2)	-	***
Co-morbidities				
CCI, mean (SD)	2 (2)	2 (2)	-	ns
BMI, mean (SD)	28.5 (4.6)	26.7 (4.9)	25.0 (3.3)	*
Hypertension, n (%)	55 (38%)	14 (33%)	0	ns
Diabetes, n (%)	34 (23%)	4 (9.1%)	0	ns
Current smoker, n (%)	10 (7.0%)	7 (16%)	0	ns
Lab analyses				
CRP (mg/L), mean (SD) ^{1,2}	206 (134)	119 (146)	2 (3)	***
WBC (x10 ⁹ /L), mean (SD) ^{1,3}	8.0 (4.3)	6.8 (3.5)	6.5 (1.5)	ns
Lymphocytes (x10 ⁹ /L), mean (SD) ^{1,3}	0.89 (0.69)	1.06 (0.47)	2.41 (1.24)	***
Neutrophils (x10 ⁹ /L), mean (SD) ^{1,3}	6.4 (3.9)	5.1 (3.5)	3.1 (0.7)	**
Monocytes (x10 ⁹ /L), mean (SD) ^{1,3}	0.44 (0.27)	0.64 (0.35)	0.54 (0.24)	**
Outcome				
Peak severity score ⁴ , mean (SD)	4.49 (1.65)	1.80 (0.82)	-	***
Fatal outcome	12 (8.1)	0	0	

¹ Statistical tests performed: One-way ANOVA; Fisher's exact test; Pearson chi-square test. ² Peak value ³ Value at maximum lymphopenia. ⁴ Peak severity score on 7-grade composite scale (see Methods).

Abbreviations: BMI = body mass index, CCI = Charlson co-morbidity index, CRP = C-reactive protein, WBC = White blood count.

Normal range: CRP <3 mg/L, WBC 3.5-8.8x10⁹/L, lymphocytes 1.1-3.5 x10⁹/L, neutrophils 1.6-5.9 x10⁹/L, monocytes 0.2-0.8 x10⁹/L.

Table 2. Baseline characteristics of COVID-19 patients across disease severity.

Peak disease severity	Mild		Moderate		Severe		Fatal	Sig ¹
	1	2	3	4	5	6	7	
N (%)	13 (8.8)	6 (4.1)	10 (6.8)	48 (33)	19 (13)	39 (27)	12 (8.2)	
Age, mean (Range)	44 (24-72)	60 (41-72)	56 (46-78)	55 (24-76)	57 (42-74)	61 (25-77)	66 (52-78)	***
Male, n (%)	5 (38)	2 (33)	6 (60)	38 (79)	15 (79)	34 (87)	9 (75)	**
Onset to adm. ² , mean (SD)	-	10.4 (2.2)	9.4 (4.1)	10.3 (4.1)	7.6 (2.9)	11.0 (8.1)	9.9 (7.6)	ns
Length of stay ² , mean (SD)	-	5 (4)	6 (4)	12 (7)	25 (10)	33 (17)	-	***
Co-morbidities								
CCI, mean (SD)	1 (2)	2 (1)	1 (1)	2 (2)	2 (1)	2 (1)	3 (1)	*
BMI, mean (SD)	24.1 (4.5)	25.1 (2.2)	26.0 (3.2)	30.3 (4.2)	29.2 (5.3)	28.6 (4.7)	28.6 (2.4)	***
Hypertension, n (%)	1 (8.3)	0 (0)	2 (20)	20 (42)	8 (42)	15 (38)	9 (75)	**
Diabetes, n (%)	2 (17)	0 (0)	1 (10)	14 (29)	5 (26)	9 (23)	3 (25)	ns
Current smoker, n (%)	0 (0)	0 (0)	2 (20)	5 (11)	1 (5.3)	2 (5.3)	0 (0)	ns
Medications prior to admission								
ACE-I, n (%)	0 (0)	0 (0)	0 (0)	5 (10)	1 (5.3)	4 (10)	1 (9.1)	ns
Immunosuppressant, n (%)	1 (7.7)	0 (0)	0 (0)	4 (8.3)	2 (11)	5 (13)	1 (8.3)	ns
Laboratory analyses³								
CRP ⁴ , mean (SD)	6 (10)	102 (54)	137 (143)	161 (87)	236 (114)	288 (106)	364 (119)	***
PCT ⁵ , mean (SD)	0.1 (0.0)	1.0 (2.0)	0.5 (1.0)	0.5 (1.0)	2.3 (6.9)	16.3 (58.2)	17.3 (33.5)	ns
WBC ⁶ , mean (SD)	4.7 (1.6)	6.0 (1.9)	6.8 (4.9)	7.2 (2.6)	7.6 (2.7)	9.7 (5.7)	10.8 (5.3)	**
Neutrophils ⁶ , mean (SD)	2.4 (1.3)	4.7 (1.9)	5.4 (5.0)	5.5 (2.2)	6.2 (2.6)	8.1 (4.7)	9.7 (5.0)	***
Lymphocytes ⁶ , mean (SD)	1.68 (0.45)	0.76 (0.30)	0.97 (0.28)	1.06 (0.92)	0.68 (0.31)	0.72 (0.52)	0.44 (0.19)	***
Monocytes ⁶ , mean (SD)	0.48 (0.16)	0.34 (0.19)	0.42 (0.25)	0.49 (0.28)	0.43 (0.27)	0.44 (0.29)	0.30 (0.23)	ns
Ct-value, mean (SD)	27 (7)	24 (6)	27 (6)	26 (6)	26 (5)	24 (7)	21 (6)	ns
Seroconversion ⁷ , n (%)	9 (75)	4 (67)	9 (100)	36 (97)	17 (100)	37 (100)	10 (91)	**

¹Statistics performed: One-way ANOVA, Fisher's exact test. ²days, ³Peak values: CRP, PCT; Nadir values: lymphocyte count, Ct-value; WBC, neutrophil and monocyte counts at timepoint for lowest lymphocyte count. ⁴mg/L, ⁵ug/L, ⁶10⁹ cells/L. ⁷At any sampling timepoint. Abbreviations: n= number of patients, BMI= body mass index, CCI = Charlson co-morbidity index, ACE-I = angiotensin converting enzyme-inhibitor, CRP = C-reactive protein, PCT = procalcitonin, WBC = white blood cell count. Normal range: CRP <3 mg/L, PCT<0.05, WBC 3.5-8.8x10⁹/L, lymphocytes 1.1-3.5 x10⁹/L, neutrophils 1.6-5.9 x10⁹/L, monocytes 0.2-0.8 x10⁹/L.